<<

Why study parasites?

 The weird and bizarre

House, M.D. Episodes

The superb diagnostician everyone loves to hate Hugh Laurie

7 (1-07) "Fidelity" December 28, 2004

29 (2-07) "Hunting" November 22, 2005 Echinococcosis

32 (2-10) "Failure to January 10, 2006 Cerebral malaria Communicate"

43 (2-21) "Euphoria, Part 2" May 3, 2006 Primary amoebic meningoencephalitis by Naegleria fowleri

50 (3-04) "Lines in the Sand” September 26, 2006 Baylisascaris

60 (3-14) "Insensitive" February 13, 2007 Diphyllobothrium latum causing Vitamin B12 deficiency

73 (4-03) "97 Seconds" October 9, 2007 Strongyloidiasis

83 (4-13) “No More Mr. Nice Guy" April 28, 2008 Chagas disease

Why study parasites?

 The weird and bizarre  Infectious diseases: Emerging and re-emerging diseases Biodefense/bioterrorism links

1 Why study parasites?

NIAID Biodefense Research: Category A, B & C Priority Pathogens  Infectious diseases: Emerging and re-emerging diseases Biodefense/bioterrorism links

Why study parasites?

 The weird and bizarre  Infectious diseases: Emerging and re-emerging diseases Biodefense/bioterrorism links  Interesting Biology Unique eukaryotic biological properties

Unique Eukaryotic Biology

• Antigenic variation • • GPI-anchored proteins • • Bent DNA helices • • Polycistronic transcription • Kinetoplast DNA (kDNA)(kDNA) • Trans-splicing of RNAs • • Mitochondrial RNA editing

2 Why study parasites?

 The weird and bizarre  Infectious diseases: Emerging and re-emerging diseases Biodefense/bioterrorism links  Interesting Biology Unique eukaryotic biological properties  Global Public Health Tropical diseases affecting some of the worlds poorest populations  Diverse group of organisms ranging from microscopic to large multicellular organisms. - unicellular eukaryotes Platyhelminthes - flatworms Nematodes - roundworms Arthropods - insects and ticks (parasitic or that transmit parasites)

Number of people infected/affected by parasitic diseases

 Disease with HIGH mortality:  Disease with morbidity and QL losses:

 Malaria - 489 M

 Sleeping Sickness 0.5 M  Schistosomiasis - 200 M

 Chagas disease - 18 M  Onchocerciasis - 18 M  Visceral - 4 M  Filiariasis - 650 M

 Ascariasis - 1.4 B

** Calculated World Pop  Hookworm diseases - 1.3 B 1/26/09:  Cutaneous leishmaniasis - 8 M 6.88 Billion  Food and waterborne

Note: statistics from ~2004 protozoan - 1.5 B

Why study parasites?

 The weird and bizarre  Infectious diseases: Emerging and re-emerging diseases Biodefense/bioterrorism links  Interesting Biology Unique eukaryotic biological properties  Global Public Health Tropical diseases affecting some of the worlds poorest populations  Diverse group of organisms ranging from microscopic to large multicellular organisms. Protozoa - unicellular eukaryotes Platyhelminthes - flatworms Nematodes - roundworms Arthropods - insects and ticks (parasitic or that transmit parasites)

3 MICROBIO590S Parasitology

More Concepts and Terms

“…no matter how we set ourselves off from nature we remain a part of it, and thus we invariably share parasites with the other species in which we live.” Julius P. Kreier PARASITIC PROTOZOA

Ecto- vs. Endoparasite

 Ectoparasites live on, but not in their hosts. Protozoan Ichthyophthirius that causes fish “Ick”

 Endoparasites live within the body and of their hosts. The majority of parasites to be discussed. Protozoan that causes African Sleeping sickness.

4 Facultative vs. Obligate

 Facultative - usually a free-living organism but can invade host under certain conditions. Can cause severe disease. Naegleria fowleri

 Obligate - most parasites require a host for at least one stage of its life cycle. Some parasitic worms have free-living larval stages.

Intermittent vs. Permanent

 Intermittent/ temporary - micropredation - “parasite” feeds on the host and then leaves.

 Permanent - parasite that lives its entire adult life on or within the host. Most of the parasites we discuss are permanent.

Life cycles

Entamoeba histolytica  Direct Life Cycle - parasite passes from one host to the next through contaminated food/water, air, or sexual intercourse.

 Indirect Life Cycle - parasite passes from one host to the next through a vector and/or intermediate host. Diphyllobothrium latum Many parasites have complex indirect life cycles.

5 Vectors - Actively transmit parasites

 Mechanical Vector - no multiplication or development of parasite takes place. Horse fly

 Biological Vector - Tsetse fly either multiplication or development takes place.

Transmission of 2 related protozoa

Tsetse fly

Horse fly

 Feeds often moving  Proboscus used for front legs and mouth blood meal - longer parts vigorously. feeding period.   Trypanosoma evansi bloodstream form is remains on the mouth ingested - develop to parts - no biological procyclic form - migrate development occurs. and develop to infective epimastigotes (new form).

Hosts

 Definitive host - where sexual occurs. If there is no sexual reproduction documented, then it is the host that is most important to humans.

 Typically a vertebrate. Exception -  Intermediate host - where asexual replication or parasite development occurs.  Paratenic host - transport host, but parasites do not develop in this host.  Reservoir host - any animal that carries an infection that can serve as a source of infection to human and other animals.  Accidental host - parasite enters or attaches to other than the normal host. Parasites usually do not survive in the wrong host, but can cause serious disease (Toxocara).

6 Example

Intermediate Paratenic Bridging the gap between human Host Host And small fish/copepod.

Copepod Monoecious Intermediate Hermaphroditic Host Definitive Diphyllobothrium Host latum Free-swimming stage

Summary

 Ecto- vs. Endparasite

 Facultative vs. Obligate

 Intermittent vs. Permanent

 Vectors

 Hosts

 Life Cycles

 Know these definitions

 Be able to compare/contrast using specific examples

Infectious Diseases

 Emerging Infectious Diseases

 New diseases (mainly viral agents)  Re-emerging Infectious Diseases

 Tuberculosis, Poliomyelitis  Neglected Diseases

 AIDS, Malaria, Tuberculosis

 Typically called the big 3.  Most (“The Great”) Neglected Diseases

 Many tropical parasitic diseases

7 Emerging Infectious Disease

 Infectious diseases whose incidence in humans has increased in the past 2 decades or threatens to increase in the near future have been defined as "emerging." These diseases respect no national boundaries include:

 New infections resulting from changes or evolution of existing organisms (host and/or pathogen)

 Known infections spreading to new geographic areas or populations  Previously unrecognized infections appearing in areas undergoing ecologic transformation

 Old infections re-emerging as a result of antimicrobial resistance for known agents or breakdowns in public health measures.

Emerging(re) Infectious Diseases

 Nearly all are zoonotic or species jumping agents -HIV Species Jumping -Influenza -Hepatitis C and E

-E. coli 0157:H7 -Cryptosporidium -Ebola -Hantavirus Zoonoses -Lyme disease -nvCJD -Trypanosomiasis -West Nile Virus

Zoonoses

 Zoonoses - transmission of the infectious agent to humans from an animal reservoir. No establishment of a permanent new life cycle solely in humans (still requires animals).

 Species jumping - the infectious agent derives from an ancient animal reservoir, but has established a new life cycle in humans that DOES NOT require an animal transmission phase any longer.

8 Contributing Factors for Zoonoses

 Pathogen evolution (adaptation)

 Mutations

 Host condition

 Vaccination

 Immunological disorders

 Host population

 Urban crowding (land use)

 Host demographics & behavior

 Global travel

 Environmental

 Climate

 Destruction

 Public Health breakdown

Dealing with Zoonoses

 Why are the pathogens jumping? Can we predict this?

 Who will be the world’s doctor? WHO, UN - need to get rid of political links?

 Who will be the world’s expert on zoonoses?

 Develop new strategies to deal specifically with emerging zoonoses.

 Surveillance will be key, but also greater involvement of field and basic science research.

Infectious Diseases

 Emerging Infectious Diseases

 New diseases (mainly viral agents)  Re-emerging Infectious Diseases

 Tuberculosis, Poliomyelitis  Neglected Diseases

 AIDS, Malaria, Tuberculosis

 Typically called the big 3.  Most (“The Great”) Neglected Diseases

 Many tropical parasitic diseases

9 Great Neglected Diseases

 HAT is just one example.

 Pharmaceutical industry is ONLY part of the problem.

 Improved economic situation

 Improved public health

 Global alliances are extremely important

 We are now on the way!

 Medecins sans Frontieres

 Roll back Malaria

 DNDi - Drugs for Neglected Diseases initiative

Human African Trypanosomiasis (HAT)

 Classical example of a zoonotic emerging infection, 1890-1930.

 Leading public health problem in Africa at that time, colonialism brought the disease to new areas with a 2/3 death rate.

 Nearly eliminated by 1960 using population screening, case treatment, chemoprophylaxis, and vector control.

 Currently classified by WHO as a re-emerging and uncontrolled disease.

HAT Nearly Eliminated in 1962!

Human African Trypanosomiasis, central Africa, 1926-1999

HAT: re-emerging, Neglected Tropical Disease

10 HAT: More recent data

2004

Classified by WHO as a re-emerging uncontrolled disease.

How was control successful?

Then….

……..and Now.

Card agglutination Anion Exchange Centrifugation Technique Molecular Tools

Time consuming Sensitive Expensive Still under development Additional equipment

Large # of false +’s

11 Estimating Disease Burden

 > 60 M people at risk, only about 3-6 M are screened for HAT.

 Health facilities lacking in disease foci areas.

 Little if any public health measures being implemented.

 Huge political conflict and insecurity in epidemic foci.

 Clinical diagnosis is difficult until late stage.  Intermittent fever - malaria?

 Weight lose - AIDS?  Diagnostics - false negatives

Barriers to control HAT

 Insufficient resources - developing countries

 War and civil disturbances = arefugees

 No vaccine = no prevention

 Crisis in chemotherapeutics

 Melarsoprol was 95% effective, but in 1997 resistance up to 30% was emerging in Uganda, Sudan and Angola (DRofC little data).

 Arsenal of therapeutic drugs is minimal (~6)

 Toxicity -drugs kill 4-10% of the patients.

Treatments for HAT

Drug Indication Status (summer 2000)

Pentamidine early stage donations phasing out Suramin early stage halt of production Melarsoprol CNS resistance and future production uncertain Eflornithine CNS not produced Nifurtimox CNS halt of production

Recent developments are that all five are being produced and donated by the WHO for five years

Eflornithine - called the “resurrection drug” May 2001 - Aventis agreement - donate eflornithine for 5 years + 25 million in support of field studies etc. 2006 - agreement ran out NOW????

12 Africa’s burden

Sub-Saharan Africa Has the Highest Prevalence of Nine Neglected Tropical Diseases

PLoS Med 2(11): e336 doi:10.1371/journal.pmed.0020336

Do you know these public health workers?

13 • World’s first peer-reviewed, open-access journal devoted to the NTDs • Launch supported by Bill and Melinda Gates Foundation • Papers on pathology, epidemiology, treatment, control, prevention • Magazine section devoted to policy and advocacy

• International editorial board—half of the Associate Editors are from endemic countries

“It is expected that the journal will be both catalytic and transformative in promoting science, policy, and advocacy for these diseases of the poor.” —Peter Hotez, Editor-in-Chief

Papers Discussion

Common features of the NTDS

• diseases that have burdened humanity for centuries • cause immense suffering

• cause life-long disabilities

• impair childhood growth & development

• poverty-promoting conditions

• disproptionate effect on the poor

• shortage of safe and effective treatments

• gap in attention for global R & D

• no commericial markets for products that target these diseases

PLoS Med 2(11): e336 doi:10.1371/journal.pmed.0020336

14